Article [Working Title]: A multi-ancestry genome-wide association study identifies novel candidate loci in the RARB gene associated with hypertensive disorders of pregnancy Short Title: Multi-ancestry GWAS of hypertension in pregnancy Jasmine A. Mack^{1,2}, Adam Burkholder¹, Farida S. Akhtari¹, John S. House¹, Ulla Sovio², Gordon C.S. Smith², Charles P. Schmitt¹, David C.Fargo¹, Janet E. Hall¹, Alison A. Motsinger-Reif¹ ¹ National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA ² University of Cambridge, Department of Obstetrics and Gynaecology, Cambridge, UK, CB2 0SW Corresponding author: Alison Motsinger-Reif alison.motsinger-reif@nih.gov Word count: 7917

2

31

32 Abstract

33 Background

- 34 Genetic factors related to pregnancy-related traits are understudied, especially among
- ancestrally diverse cohorts. This study assessed maternal contributions to hypertensive
- 36 disorders of pregnancy (HDP) in multi-ancestry cohorts.

37 Methods

- We performed a genome-wide association study of HDP using data from the
- 39 Personalized Environment and Genes Study (PEGS) cohort (USA) with validation in the
- 40 UK Biobank (UKBB). We performed gene-level and gene-set analyses and tested the
- 41 association of polygenic scores (PGS) for systolic blood pressure (SBP), preeclampsia
- 42 (PE), and gestational hypertension (GH).

43 **Results**

- 44 We identified two novel maternal genome-wide significant associations with HDP. The
- lead independent variants were rs114954125 on chromosome 2 (near *LRP1B*; OR
- 46 (95% CI): 3.03 (2.05, 4.49); *P*=3.19 x 10⁻⁸) and rs61176331 on chromosome 3 (near
- 47 RARB; OR (95% CI): 3.09 (2.11, 4.53); P=7.97×10⁻⁹). We validated rs61176331 in the
- UKBB ($P=3.73 \times 10^{-2}$). When aggregating SNPs by genes, RARB ($P=1.36 \times 10^{-3}$) and
- 49 RN7SL283P ($P=2.56 \times 10^{-2}$) were associated with HDP. Inflammatory and
- 50 immunological biological pathways were most strongly related to HDP-associated
- 51 genes. While all blood pressure and HDP-related PGS were significantly associated
- with HDP in PEGS, the SBP PGS was a stronger predictor of HDP (area under the
- curve (AUC): 0.57; R^2 =0.7%) compared to the PE PGS (AUC: 0.53; R^2 =0.2%).

54 Conclusion

- 55 Our study is the first to identify and validate maternal genetic variants near RARB
- associated with HDP. The findings demonstrate the power of multi-ancestry studies for
- 57 genetic discovery and highlight the relationship between immune response and HDP
- 58 and the utility of PGS for risk prediction.
- 59
- 60 ClinicalTrials.gov Identifier for PEGS: NCT00341237

- 62
- 63
- 64

66 Non-standard Abbreviations and Acronyms

| AFR | African ancestry |
|------|--|
| AMR | Admixed American ancestry |
| EAF | Effect allele frequency |
| EAS | East Asian ancestry |
| EUR | European ancestry |
| GH | Gestational hypertension |
| GWAS | Genome-wide association study |
| HDP | Hypertensive disorders of pregnancy |
| KEGG | Kyoto Encyclopedia of Genes and Genomes |
| MAC | Minor allele count |
| MIM | Mendelian Inheritance in Man |
| PCA | Principal components analysis |
| PE | Preeclampsia |
| PEGS | Personalized Environment and Genes Study |
| PGS | Polygenic score |
| SAS | South Asian ancestry |
| SNP | Single nucleotide polymorphism |
| SNV | Single nucleotide variant |
| UKBB | UK Biobank |

4

81

82 Introduction

Hypertensive disorders of pregnancy (HDP) are a heterogeneous set of adverse 83 pregnancy outcomes that occur in the perinatal period comprising gestational 84 hypertension (GH), preeclampsia/eclampsia (PE), chronic, pre-existing hypertension 85 86 with or without superimposed PE, and postpartum PE. HDP occur in approximately 5-10% of pregnancies worldwide¹ although prevalence varies by disease subtype and 87 region^{2,3}. HDP incidence increased by 11% from 1990 to 2019⁴. Globally, an estimated 88 50,000-75,000 deaths occur annually due to PE⁵. HDP are the primary cause of 89 maternal morbidity and mortality² in high-resource countries and a secondary cause 90 globally⁶. 91 92

There is racial and ethnic disparity regarding HDP prevalence and incidence as well as
the contributing risk factors. Black, Hispanic, and Indigenous individuals experience
disproportionately high rates of HDP compared to White individuals^{7,8}. Risk factors for
HDP include pre-pregnancy body mass index (BMI) > 25 kg/m², nulliparity, prior GH,
maternal age of more than 35 years, family history of HDP, and pre-existing
hypertension⁹.

99

The pathophysiology of HDP is not fully understood, but dysfunction in placental growth factors and regulators of angiogenesis are suggested mechanisms, with maternal and fetal contributions¹⁰. This mechanism is hypothesized to be associated with diminished placental perfusion causing systemic vascular endothelial dysfunction through the

| 104 | release of antiangiogenic factors from the placenta ^{11,12} . Placental hypoperfusion is |
|-----|--|
| 105 | thought to be caused by failure of transformation of uterine spiral arteries into low- |
| 106 | resistance conduits, which is a normal feature of invasion by extravillous |
| 107 | cytotrophoblast ^{13,14} . Failure of spiral artery transformation has been linked to fetal |
| 108 | growth restriction, miscarriage, and PE ¹⁴ . Moreover, placental factors can interact with |
| 109 | maternal genetics, epigenetics, and environmental factors to influence the response to |
| 110 | placental dysfunction ¹⁵ . Maternal immune system changes are involved in the |
| 111 | development and pathogenesis of PE ¹⁶⁻²² , but the mechanisms are incompletely |
| 112 | understood. |
| 113 | |
| 114 | Early genetic studies of HDP have been predominantly focused on individuals of |
| 115 | European ancestry ^{23,24} . In research in large cohorts with genetic data, participants from |
| 116 | underrepresented racial/ethnic groups are consistently excluded from published |
| 117 | analyses due to small sample sizes and the use of sparse methods to account for |
| 118 | population structure ^{25–27} . |
| 119 | |
| 120 | Prior genome-wide association studies (GWAS) of PE have revealed strong signals |
| 121 | near the FLT1 gene (MIM:165070) based on a meta-analysis of fetal genotypes from |
| 122 | five cohorts, of which all participants were of European ancestry: Genetics of Pre- |
| 123 | Eclampsia (GOPEC), Avon Longitudinal Study of Parents and Children (ALSPAC), |
| 124 | deCODE, Norwegian Mother and Child (MoBa), and Finnish Genetics of Pre-eclampsia |
| 125 | Consortium (FINNPEC) ²⁴ . The largest maternal genome-wide multi-ancestry meta- |
| 126 | analysis of PE and GH was conducted in cohorts comprising FinnGen, Estonian |

6

biobank, Genes and Health, Michigan Genomics Initiative, Mass General Brigham 127 Biobank, Biobank Japan, BioMe Biobank, InterPregGen Consortium, Trøndelag Health 128 Study (HUNT), UKBB, Penn Medicine Biobank, and Nulliparous Pregnancy Outcomes 129 Study: Monitoring Mothers-to-Be (nuMoM2b)²⁸. Among 31,091 HDP cases assessed in 130 the meta-analysis, 83% were of European ancestry. Multi-ancestry meta-analyses have 131 132 been conducted in diverse cohorts such as the Pan UK Biobank (UKBB), but the control groups of the GWAS also included female UKBB participants who have never been 133 pregnant²⁹. 134

135

To increase diversity and support the representation of non-European populations in 136 genomics research, GWAS that include minority racial and ethnic groups can be 137 conducted in currently available data from diverse cohorts. The results can be stratified 138 by ancestry, and meta-analyses can jointly model effects in a multi-ancestry analysis. 139 Building upon previous multi-ancestry genetic studies, we conducted multi-ancestry 140 GWAS in whole-genome sequencing (WGS) data from a discovery cohort from the 141 North Carolina-based Personalized Environment and Genes Study (PEGS) using a 142 143 case-control study design. The joint modeling exhibited improved power for genetic discovery, enabling the first discovery of a maternal genetic association near the retinoic 144 145 acid receptor (RARB) gene (MIM: 180220) with HDP. We validated this association in 146 the UKBB and a meta-analysis in PEGS and the UKBB. In downstream analyses, we performed gene-level analysis and gene-set analyses to elucidate the biological 147 mechanisms involved in HDP. Further, in the PEGS dataset, we assessed the predictive 148

ability of existing polygenic scores (PGS) for PE and GH, with HDP in predicting risk of

149

7

| 150 | these conditions. |
|-----|--|
| 151 | |
| 152 | Methods |
| 153 | The data used in this study are available to researchers through application to dbGAP |
| 154 | the UK Biobank (https://www.ukbiobank.ac.uk/register-apply/). Reference panel data |
| 155 | from the 1000 Genomes Project and polygenic scores from the PGS Catalog are |
| 156 | publicly available. The Major Resources Table provides details. The summary statistics |
| 157 | that support the study findings are available from the corresponding author upon |
| 158 | reasonable request. |
| 159 | |
| 160 | Study Populations |
| 161 | PEGS Cohort |
| 162 | For the discovery cohort, we selected participants from PEGS, a long-term, prospective |
| 163 | cohort based in North Carolina ³⁰ . PEGS collects extensive clinical, genetic, |
| 164 | environmental, and self-reported health information to investigate disease etiology and |
| 165 | risk factors across phenotypes in a diverse group of 19,685 individuals. |
| 166 | |
| 167 | Participants are administered the Health and Exposure Survey, External Exposome |
| 168 | Survey, and Internal Exposome Survey that request information on sociodemographic |
| 169 | factors, individual and family medical history, lifestyle factors, medication use, diet, and |
| 170 | physical environmental exposures from childhood to adulthood. While PEGS exclusion |

171 criteria include women who self-report being pregnant, a small number of participants

8

were pregnant when they completed the Internal Exposome Study, as this was

administered later in the data collection process.

174

For a subset of 4,737 PEGS participants who provided blood and urine samples, WGS
data were processed, with the optional return of results for select health conditions. The
Broad Institute sequenced all samples on the NovaSeq 6000 platform with a target
genome-wide read depth of 30x (24 samples per flow cell).

180 For downstream analyses, we removed related individuals in the PEGS genomic cohort by analyzing the genotypes of all individuals using KING 2.2.5³¹ to generate pairwise 181 kinship estimation. We excluded second-degree or closer relatives using a kinship 182 threshold of 0.0884. We estimated genome-wide local ancestry on the autosomes and 183 X chromosome using RFMix version 2, a discriminative modeling approach³². We 184 classified genomic positions by five genetic similarity groups: African (AFR), Admixed 185 American (AMR), East Asian (EAS), European (EUR), and South Asian (SAS). We 186 classified individuals into one of the genetic similarity groups if any genome-wide local 187 188 ancestry proportion was greater than 0.50. Otherwise, we classified participants as "None". 189

190

The PEGS cohort is a registered clinical trial, and all participants provided written
 informed consent (ClinicalTrials.gov Identifier: NCT00341237)³⁰. We obtained the data
 used for the analyses from PEGS Data Freeze version 2.0 created in August 2021. The

9

194 Supplemental Methods section provides details on genome sequencing, quality

- 195 control, and local ancestry inference.
- 196
- 197 UK Biobank
- 198 For the validation cohort, we selected participants from the UK Biobank (UKBB). UKBB
- is a large, deeply phenotyped genomic cohort comprising 488,366 participants aged 40-
- 69 years at recruitment from 2006 to 2010. About 6% of participants (>30,000) identified
- as having a non-White ethnic background^{25,33}. Genetic data are linked to electronic
- health records and survey data, and UKBB has information on diagnosis history, brain
- imaging, medication use, lifestyle factors, deprivation indices, environmental exposure
- 204 data, and sociodemographic characteristics.
- 205
- 206 Ethical approval for UKBB was obtained from the North West Centre for Research
- 207 Committee (11/NW/0382). Informed consent was obtained for all participants. The
- following work described was approved by the UKBB team under Application No.
- 57849. We obtained predominant ancestry assignments from UKBB Returned Dataset
- 210 2442³⁴. The **Supplemental Methods** provides details on genotyping and genetic
- similarity groups in UKBB.
- 212
- 213 Case-Control Definition

Figure S1 outlines the steps taken to define cases and controls in the PEGS cohort. Because the data available for PEGS and UKBB are not standardized, we defined cases and controls separately for each cohort and harmonized the case-control sets as

10

217 much as possible. The **Supplemental Methods** section provides details on case-

- 218 control definition.
- 219
- 220 <u>PEGS</u>
- 221 We defined cases and controls for 4,933 PEGS participants who self-reported at least
- one pregnancy. After filtering, there were 202 GH cases, which is the primary outcome,
- 223 92 PE cases, 78 GH only cases, 223 GH/PE cases, and 1,569 controls. Table S1 lists
- the phenotypes and survey questions used to define cases and controls.
- 225
- 226 <u>UKBB</u>
- 227 We defined cases and controls in the UKBB population using the International
- 228 Classification of Diseases (ICD) codes (ICD10) for pregnancy-induced hypertension
- with and without significant proteinuria (PE and hemolysis, elevated liver enzymes and
- low platelets (HELLP) syndrome), eclampsia, and unspecified maternal hypertension
- (Table S1). After filtering, there were 1,319 HDP cases and 2,050 controls.

232

233 Statistical Analysis

For each cohort, we calculated frequencies and proportions for categorical variables and mean/standard deviation for normally distributed continuous variables, including covariates and sociodemographic characteristics. For continuous variables without normal distribution, we report median and interquartile ranges. We estimated *P* values by Fisher's exact test to assess associations among covariates and performed t-tests

11

for continuous variables. For variables without normal distribution, such as BMI, we

- 240 used the Mann-Whitney U test.
- 241

242 Genome-wide Association Study for Common Variants

243 We conducted GWAS (MAF>=0.03) using multivariable logistic regression to model the

odds of HDP, assuming an additive allelic genetic model. We adjusted for the top 10

genetic principal components, self-reported race/ethnicity, age and BMI at enrollment,

and gravidity. We used PLINK2.0³⁵ for all GWAS with Firth-corrected logistic regression

²⁴⁷ modeling to account for case-control imbalance³⁶. Because information on gravidity was

available for few UKBB participants, we excluded this covariate in the UKBB analyses.

249 We included genotyping batch as a covariate in the UKBB analyses given that two types

of arrays were used in genotyping with 106 batches²⁵. We used a threshold of $P < 10^{-10}$

 5×10^{-8} for genome-wide significance and $P < 1 \times 10^{-6}$ for suggestive significance.

252

In addition to the main outcome of HDP, we performed GWAS for three other
phenotypes in the PEGS discovery cohort (PE, GH without PE, and GH and/or PE) for
all individuals and separately for the AFR and EUR similarity groups. We adjusted for
within-group variation using the top 10 principal components, age and BMI at
enrollment, and gravidity. The AMR, EAS, and SAS similarity groups had insufficient
numbers of participants to perform stratified analyses (Table 1).

259

To validate our findings, we filtered GWAS summary statistics from the PEGS multiancestry analysis to include only variants with suggestive association ($P < 1 \times 10^{-6}$).

12

| 262 | We assessed these variants in the UKBB using harmonized cases and controls. We |
|-----|--|
| 263 | used GCTA-COJO for conditional and joint analyses to identify independently |
| 264 | associated loci ³⁷ . We used METAL to perform inverse variance-weighted meta-analyses |
| 265 | for variants with suggestive association in PEGS and UKBB ³⁸ . |

266

267 <u>Gene-based Association Analysis and Gene-set Analysis</u>

268 To increase statistical power for discovery, we used MAGMA to perform gene-set

association analysis, adjusting for the top 10 genetic principal components, self-

reported race/ethnicity, age and BMI at enrollment, and gravidity. We used Ensembl

annotation on GRCh38 to map the SNVs from the GWAS to 31,427 genes³⁹. We utilized

the results from the gene-level analysis to perform gene-set analysis in MAGMA^{40,41}.

273 We used the Kyoto Encyclopedia of Genes and Genomes (KEGG) to define gene sets

by biological pathways and conditions^{42,43}. To control the false discovery rate (FDR), we

used the Benjamini-Hochberg method to adjust *P* values from the statistical analyses for

276 multiple comparisons. We define statistical significance by an adjusted *P* value of 0.05

and suggestive FDR-corrected significance by an adjusted *P* value of 0.10.

278

279 Application of Polygenic Scores

To assess the predictive value of SBP, PE, and GH for HDP in PEGS, we applied an SBP PGS derived from the UKBB female sub-cohort in Kauko et al.⁴⁴ and separate scores for SBP, PE, and GH from meta-analyses in Honigberg et al.²⁸. We separately computed the four PGS in the PEGS pregnancy (n = 1,771) and female sub-cohorts (n

13

= 3,102) to model HDP and essential hypertension, respectively. We standardized each
 PGS. The Supplemental Methods section provides details.

286

- 287 We performed logistic regression with Firth correction to assess the association
- between HDP risk and the standardized PGS, adjusting for the top ten genetic principal
- components, self-reported race/ethnicity, age and BMI at enrollment, and gravidity. For
- further validation, we tested the association of each PGS with essential hypertension in
- the PEGS female sub-cohort, adjusting for the same covariates except gravidity.
- Additionally, we performed stratified analyses for the AFR and EUR genetic similarity

groups. For each PGS, we report odds ratios per standard deviation with a 95% CI. We

- calculated the AUC for each model using the pROC package in R to assess
- discriminative ability. All PGS analyses were performed in R 4.3.1 with a significance

threshold of 0.05.

297

The Major Resources Table in the **Supplemental Materials** provides details on data and code availability.

300

301 **Results**

In the PEGS cohort, participants with HDP (11.4% of the study sample) were younger,

had a higher BMI at enrollment, and had more pregnancies compared to participants in

- the control group (*P*<0.001; **Table 1**). Among HDP cases, 4.5% experienced recurrent
- diagnoses of PE, and 18.8% experienced GH during two or more pregnancies.
- Race/ethnicity distribution, education level, and income were similar for the case and

| 307 | control groups (Table 1). In the UKBB cohort, race/ethnicity, predominant genetic |
|-----|---|
| 308 | similarity group, and education level were similar for cases and controls (Table S2). |
| 309 | Similar to PEGS, UKBB participants with HDP were younger (P=0.024) and had a |
| 310 | higher BMI at recruitment (P<0.001) compared to controls. |
| 311 | |
| 312 | Novel Maternal Loci Identified on RARB |
| 313 | In the PEGS GWAS, 11 variants in two loci met genome-wide significance (Figure 1A; |
| 314 | Table S3) for HDP. An association was found for a significant novel candidate region in |
| 315 | the maternal genome (202 cases and 1,569 controls) consisting of intergenic variants |
| 316 | near the low-density lipoprotein (LDL) receptor-related protein 1B (LRP1B; |
| 317 | MIM:608766) gene on chromosome 2 (Figure 1B). A stronger signal was observed for |
| 318 | a region identified as intronic to the RARB gene (MIM:180220) on chromosome 3 |
| 319 | (Figure 1C). The lead variant was rs61176331, with an OR of 3.09 for HDP (EAF: |
| 320 | 0.048; 95% confidence interval (95% CI): (2.11, 4.53); <i>P</i> =7.97 x 10 ⁻⁹). The second most |
| 321 | significant variant was rs114954125, with an OR of 3.03 (EAF: 0.051; 95% CI: (2.05, |
| 322 | 4.49); P=3.19 x 10 ⁻⁸) (Table 2). A genomic inflation factor of 1.02 indicated sufficient |
| 323 | adjustment for population stratification (Figure S2A). Conditional and joint analyses |
| 324 | confirmed that rs61176331(P_{joint} =9.56 x 10 ⁻⁹) and rs114954125 (P_{oint} =3.79 x 10 ⁻⁸) are |
| 325 | independent loci (Table 2). In results stratified by genetic similarity group, these loci had |
| 326 | larger effect sizes although the P values were attenuated. rs61176331 had an OR of |
| 327 | 6.98 and 2.37 for the AFR and EUR genetic similarity groups, respectively (Table 2; |
| 328 | Figure S2B). rs114954125 had a similar effect size as the multi-ancestry GWAS for the |
| 329 | EUR genetic similarity group, but this variant did not reach the quality control threshold |

| 330 | in the AFR genetic similarity group. We validated rs61176331 in the UKBB analysis |
|-----|--|
| 331 | (OR: 1.29; 95% CI: (1.02, 1.65); <i>P</i> =3.73 x 10 ⁻²) (Figure S2B). In the meta-analysis |
| 332 | including PEGS and UKBB, strong associations remained for the candidate region near |
| 333 | RARB (Table 2; Table S3). |
| 334 | |
| 335 | In a sensitivity analysis with three HDP subtypes as the outcome (PE, GH only, and GH |
| 336 | and/or PE; Figure S3), there was distinct attenuation of signals in the multi-ancestry |
| 337 | HDP GWAS with PE as the outcome (21 cases) (Figure S3A). In this GWAS, the |
| 338 | candidate signal on RARB was attenuated below the genome-wide significance |
| 339 | threshold while rs114954125 on chromosome 2 remained significant. (Figure S3E). |
| 340 | |
| 341 | Significant Gene-wide Associations for RARB |
| 342 | Figure 2 is a gene-based Manhattan plot. Two gene signals met the FDR-corrected |
| 343 | significance threshold—RARB (P=1.36 x 10 ⁻³) and RN7SL283P (P=2.56 x 10 ⁻³). Among |
| 344 | the top 15 most significant genes, there were strong peaks on chromosome 6 (HLA- |
| 345 | DRB5, BTNL2, RNU1-61P) and chromosome 17 (LRRC59, EME1, ACSF2; Table S4) |
| 346 | although these associations did not reach gene-wide significance. |
| 347 | |
| 348 | Immune-related Pathways Linked to HDP |
| 349 | Among the ten most significant KEGG gene sets associated with HDP were the pentose |
| 350 | phosphate pathway and the hedgehog signaling pathway (Figure 3). Gene-set analyses |
| 351 | revealed additional immune-related diseases and processes related to HDP-associated |
| 352 | genes (Table S5), but these sets, which included autoimmune thyroid disease, graft- |

16

| 353 | versus-host disease, adipocytokine signaling pathway, and allograft rejection |
|-----|---|
| 354 | (uncorrected <i>P</i> <0.05), did not meet the FDR-corrected significance threshold. |
| 355 | |
| 356 | Polygenic Score for Systolic Blood Pressure is Associated with HDP |
| 357 | We tested the association of HDP with PGS for SBP, PE, GH with HDP, and essential |
| 358 | hypertension in the PEGS female sub-cohort. Table S6 shows the number of variants |
| 359 | missing in the PEGS cohort for each PGS. In the overall model, all four PGS were |
| 360 | significantly associated with HDP (P<0.05). The AUC (0.57; 95% CI: (0.52-0.61); Figure |
| 361 | 4; Figure S5) and pseudo- R^2 (0.7%; Table S7) were the highest for the SBP PGS [1] |
| 362 | based on the UKBB. One standard deviation increase in the SBP PGS [1] was |
| 363 | associated with a 2.09-fold increase in HDP odds (95% CI: 1.40, 3.13). GH-PGS had |
| 364 | the highest OR for HDP (Figure 4). Figure S6 shows HDP prevalence by percentile for |
| 365 | each PGS. When the results were stratified by genetic similarity group, the four PGS |
| 366 | were not significantly associated with HDP in the AFR genetic similarity group, but there |
| 367 | were similar effect sizes for the overall models and for the EUR genetic similarity group |
| 368 | (Figure 4). |
| | |

369

For essential hypertension, the two SBP PGS were strongly associated with HDP in both the overall and stratified analyses (**Figure S4**). The pseudo-R² for SBP PGS [2] was the highest at 5.6% (**Table S7**). The receiver operator characteristic curves indicate that SBP PGS [2] is the most predictive of essential hypertension in PEGS (**Figure S7**), evidenced by the clear linear trend in the percentile plot (**Figure S8**).

17

376 Discussion

Our GWAS is the first to identify and validate genetic variants that are significantly associated with HDP in the maternal genome in *RARB* on chromosome 3. By leveraging a multi-ancestry study design, we increased statistical power for genetic discovery, which enabled us to confirm our findings in the clinically phenotyped UKBB cohort.

382

The two genome-wide significant loci in PEGS were also significantly associated with 383 HDP in the gene-level analysis, where *RARB* and *RN7SL283P* were the top two genes. 384 Retinoic acid receptors are essential for healthy placental and fetal development. The 385 receptor binds retinoic acid, which is the biologically active form of vitamin A that 386 facilitates cellular signaling in embryonic morphogenesis, cell proliferation, 387 differentiation, and apoptosis^{45–47}. Maternal retinol is transferred across the placenta to 388 embryos⁴⁷. All-trans-retinoic acid plays a significant role in maintaining immune balance 389 in some tissues and is linked to the etiology of PE, where greater dysregulation in 390 retinoic acid levels in the decidua (maternal endometrium) is observed in PE cases 391 compared to those with a normal pregnancy⁴⁸. A link has been suggested between 392 decidualization and the anti-angiogenic protein soluble fms-like tyrosine kinase-1 393 394 (sFLT1), with retinoic acid directly reducing sFLT1 production in the decidua, which affects early vascular development⁴⁸. Furthermore, in GWAS in a Peruvian cohort 395 focused on maternal and offspring genetic effects on PE, rs4241542, a variant that is 80 396 397 kb from the lead variant rs61176331, was associated with proteinuria in offspring 398 $(P=8.48 \times 10^{-6})^{49}$, further supporting the biological validity of this region in RARB for

18

HDP. Future research is needed to investigate the interaction at the maternal-fetal
interface, including the influence of gene-gene interaction in placental pathophysiology.

While the variant near *LRP1B* was not validated in UKBB, rs114954125 is near *RN7SL283P*, which is a pseudogene. *LRP1B* belongs to the LDL receptor family and is a tumor suppressor gene⁵⁰. In a previous candidate SNP study, the T-allele variant in *LRP1B*, rs35821928, was associated with increased maternal height and decreased maternal weight⁵¹.

407

While the MAGMA gene-set analysis did not yield pathways that met the stringent FDR-408 corrected significance threshold, the top ten most significant gene sets provide 409 intriguing insights into the probable molecular mechanisms of HDP. The pentose 410 phosphate pathway is among these notable gene sets. This metabolic pathway is 411 involved in cellular redox homeostasis, which is related to oxidative stress as a factor in 412 HDP^{11,12}. The identification of immune-response pathways and conditions such as 413 autoimmune thyroid disease, graft-versus-host disease, and allograft rejection points to 414 415 an immunological dysregulation component of HDP. This is consistent with a growing body of research focused on the immunological basis of HDP^{52,19,22,48}. 416

417

The gene-level analysis revealed a strong peak of genes at chromosome 6 that did not meet the gene-wide significance threshold. *HLA-DRB5* and *BTNL2* belong to the human major histocompatibility (HLA) complex, where they are involved in the generation of an immune response. Additionally, the adipocytokine signaling pathway connects to

19

signaling molecules originating from adipose tissue, which has been linked to various
aspects of cardiovascular health. This could indicate adipose tissue malfunction plays a
role in HDP and other cardiometabolic disorders of pregnancy such as gestational
diabetes⁵³. These suggestive findings related to immune response, inflammation, and
metabolic dysfunction call for further analysis and interpretation in large pregnancy
cohorts.

428

The differing patterns of suggestive associations in the GWAS of the composite HDP 429 430 outcome, GH, and PE in PEGS may indicate differences in etiology (Figure S3). The heterogeneous nature of HDP has led to the understanding that there are several 431 distinct PE subtypes. A two-stage placental model related to the development of PE^{19,54} 432 demonstrated that an early-onset, more severe subtype may be associated with 433 underlying genetic or environmental factors that result in abnormal placentation. In 434 435 contrast, a later-onset, less severe subtype may be a consequence of factors such as obesity, diabetes, cardiovascular disorders, or multi-fetal pregnancy¹. Further, risk 436 factors for GH and PE vary⁵⁵, supporting evidence for differing etiology across the 437 438 collection of hypertensive disorders. However, a holistic assessment of HDP that combined PE with other maternal hypertensive disorders as a phenotype for GWAS 439 440 yielded novel, overlapping risk loci identified in models of PE only and PE or other HDP⁵⁶. 441

442

443 Considering polygenic prediction, using a blood pressure PGS to predict HDP has been
444 found to be more effective than using a PE PGS for women who are non-hypertensive

20

before pregnancy⁵⁷. In this study, we assessed the predictive utility of four PGS in the 445 context of HDP and essential hypertension. While these scores were developed in the 446 White British sub-cohort of UKBB^{28,44}, our results demonstrate that an SBP PGS is a 447 strong predictor of HDP. In the stratified results, none of the scores exhibited predictive 448 value for HDP for the AFR genetic similarity group, and only the SBP scores were 449 450 significantly associated with essential hypertension. These findings highlight the need for customizing PGS development to be inclusive of varying genetic similarity 451 backgrounds to improve the accuracy of HDP risk assessment, as the study's 452 453 effectiveness in predicting HDP using a PE PGS or GH PGS does not apply to all populations. Furthermore, while the SBP PGS showed promise for HDP prediction and 454 prevention, it is worth investigating how these genetic scores could be combined with 455 other clinical and environmental factors to develop a more holistic approach to HDP 456 prediction and prevention. 457

458

This study has several limitations. First, a composite outcome like HDP can obscure 459 disparate etiologies, for example, between PE and GH. Because of the limited sample 460 461 size, we grouped the heterogeneous conditions that comprise HDP to increase power to detect genetic variant associations. Second, the results are based on data from a 462 463 particular time point for each participant. The lack of longitudinal data does not allow us to account for the continuum of risk due to factors such as maternal age and gestational 464 age at the onset of HDP. Further, the study design does not consider the recurrence of 465 complications in subsequent pregnancies. Third, the outcomes are dichotomized due to 466 467 the nature of the questionnaires completed, which may result in the oversimplification of

21

adverse pregnancy outcomes. Fourth, misclassification bias may be present, since
participants who enrolled in PEGS before a pregnancy complication occurred were
included in the control group. Fourth, there is a lack of harmonization of phenotypes
between study cohorts. While PEGS data are limited, the UKBB uses a wide variety of
diagnosis codes for phenotyping, and thus not all pregnancy-related adverse outcomes
were excluded from the control group.

474

475 Perspectives (max 250 words - Conclusion)

Variants near *RARB* were significantly associated with HDP in a multi-ancestry cohort. 476 We validated this association in a clinically phenotyped cohort. In gene-set analyses, 477 probable mechanisms associated with HDP included inflammatory and immunological 478 pathways. These findings are supported by recent research focused on the relationship 479 between retinoic acid dysregulation and PE. In-depth functional genomics investigations 480 can elucidate the molecular pathways by which genetic variations near RARB contribute 481 to the etiology of HDP, such as the influence of these variants on RARB expression, 482 epigenetic alterations, and downstream signaling pathways within the placenta and 483 484 maternal vascular system. The study demonstrates the strong predictive value of SBP PGS for HDP, but further work should investigate approaches to improve the accuracy 485 486 and inclusivity of risk assessment for HDP.

487

HDP is a complex and challenging area of obstetrics, with a significant, disproportionate
impact on maternal and fetal health across populations. While we focus on the genetic
contribution to HDP, examining the role of social determinants of health is also

| 491 | important, in part because environmental factors can influence genetic risk and the |
|-----|--|
| 492 | development of HDP. Addressing social, lifestyle, and genetic factors is imperative to |
| 493 | reduce the burden of HDP and improve maternal and fetal outcomes. Further research |
| 494 | in large, diverse pregnancy cohorts is needed to fully understand the underlying |
| 495 | mechanisms and develop effective preventative and therapeutic strategies. |
| 496 | |
| 497 | Novelty and Relevance (max 100 words) |
| 498 | What is new? |
| 499 | Genetic studies of hypertensive disorders of pregnancy (HDP) have |
| 500 | predominantly focused on individuals of European ancestry. |
| 501 | Our multi-ancestry genome-wide association study is the first to identify and |
| 502 | validate genetic variants that are significantly associated with HDP in the |
| 503 | maternal genome in the RARB gene. |
| 504 | What is relevant? |
| 505 | • We identified two novel genome-wide significant associations with HDP in the |
| 506 | maternal genome, namely rs114954125 on chromosome 2 and rs61176331 on |
| 507 | chromosome 3. The variant rs61176331 was validated in the UK Biobank. Gene- |
| 508 | set analyses revealed a suggestive association between HDP and |
| 509 | inflammatory/immunological pathways such as the pentose phosphate pathway |
| 510 | and autoimmune thyroid disease. |
| 511 | |
| 512 | Clinical/Pathophysiological Implications? |

23

| 513 • | Retinoic acid, | which binds to | RARB, inhit | bits the expression | of sFLT1 in decidua. |
|-------|----------------|----------------|-------------|---------------------|----------------------|
|-------|----------------|----------------|-------------|---------------------|----------------------|

- 514 The effects of genetic variants near RARB on the pathophysiology of HDP could
- 515 provide insights into the underlying molecular mechanisms.
- Existing genetic scores for SBP, PE, and GH were predictive of HDP and
- 517 essential hypertension in the overall PEGS cohort but were not predictive of HDP
- 518 for those of predominantly African ancestry. Future directions include the
- 519 development of genetic risk prediction modeling inclusive of large, ancestrally
- 520 diverse populations to improve utility.
- 521

522 Acknowledgements

- 523 We would like to acknowledge the participants in the PEGS and UK Biobank cohorts for
- 524 making this work possible. We would also like to thank Hannah Collins Cakar for
- 525 assistance with manuscript preparation.
- 526

527 Sources of Funding

- 528 This study was supported by the National Institutes of Health Intramural Research
- 529 Program and the NIH-Oxford-Cambridge Scholars program.
- 530
- 531 Disclosures
- 532 None
- 533
- 534
- 535

24

- 536 Supplemental Material
- 537 Supplemental Methods
- 538 Tables S1–S7
- 539 Figures S1-S8
- 540 References #58-#90
- 541

542 **References**

- Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Pract. Res. Clin. Obstet. Gynaecol.* 2011;25:391–403.
- Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. *Lancet Lond. Engl.* 2006;367:1066–1074.
- Sole KB, Staff AC, Räisänen S, Laine K. Substantial decrease in preeclampsia
 prevalence and risk over two decades: A population-based study of 1,153,227
 deliveries in Norway. *Pregnancy Hypertens.* 2022;28:21–27.
- Wang W, Xie X, Yuan T, Wang Y, Zhao F, Zhou Z, Zhang H. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population-based study. *BMC Pregnancy Childbirth*.
 2021;21:364.
- 556 5. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. *Semin.* 557 *Perinatol.* 2012;36:56–59.
- 6. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of
 maternal mortality, 1990-2015: a systematic analysis for the Global Burden of
 Disease Study 2015. *Lancet*. 2016;388:1775–1812.
- Fasanya HO, Hsiao CJ, Armstrong-Sylvester KR, Beal SG. A critical review on the
 use of race in understanding racial disparities in preeclampsia. *J. Appl. Lab. Med.* 2021;6:247–256.
- Johnson JD, Louis JM. Does race or ethnicity play a role in the origin,
 pathophysiology, and outcomes of preeclampsia? An expert review of the
 literature. *Am. J. Obstet. Gynecol.* 2022;226:S876–S885.

- Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ*. 2016;353:i1753.
 Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and
- Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and
 treatment. SAGE Open Med. 2019;7:2050312119843700.
- 572 11. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP.
 573 Pathophysiology of hypertension during preeclampsia: linking placental ischemia
 574 with endothelial dysfunction. *Am. J. Physiol.-Heart Circ. Physiol.* 2008;294:H541–
 575 H550.
- LaMarca B. Endothelial dysfunction. An important mediator in the pathophysiology
 of hypertension during preeclampsia. *Minerva Ginecol.* 2012;64:309–320.
- 57813.Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and579treatment. SAGE Open Med. 2019;7:2050312119843700.
- 14. Lyall F, Bulmer JN, Kelly H, Duffie E, Robson SC. Human trophoblast invasion and spiral artery transformation. *Am. J. Pathol.* 1999;154:1105–1114.
- 15. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L, Global
 Pregnancy Collaboration. Subtypes of preeclampsia: recognition and determining
 clinical usefulness. *Hypertension*. 2021;77:1430–1441.
- 16. Lu H-Q, Hu R. The role of immunity in the pathogenesis and development of preeclampsia. *Scand. J. Immunol.* 2019;90:e12756.
- Staff AC, Fjeldstad HE, Fosheim IK, Moe K, Turowski G, Johnsen GM, AlnaesKatjavivi P, Sugulle M. Failure of physiological transformation and spiral artery
 atherosis: their roles in preeclampsia. *Am. J. Obstet. Gynecol.* 2022;226:S895–
 S906.
- Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW Jr, Wallace
 K, LaMarca B. The role of inflammation in the pathology of preeclampsia. *Clin. Sci.* 2016;130:409–419.
- LaMarca B. The role of immune activation in contributing to vascular dysfunction
 and the pathophysiology of hypertension during preeclampsia. *Minerva Ginecol.* 2010;62:105–120.
- Aneman I, Pienaar D, Suvakov S, Simic TP, Garovic VD, McClements L.
 Mechanisms of key innate immune cells in early- and late-onset preeclampsia.
 Front. Immunol. 2020;11:1864.
- Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for immune cell
 involvement in decidual spiral arteriole remodeling in early human pregnancy. *Am. J. Pathol.* 2009;174:1959–1971.

- LaMarca B, Cornelius D, Wallace K. Elucidating immune mechanisms causing
 hypertension during pregnancy. *Physiology*. 2013;28:225–233.
- Gray KJ, Kovacheva VP, Mirzakhani H, Bjonnes AC, Almoguera B, DeWan AT,
 Triche EW, Saftlas AF, Hoh J, Bodian DL, et al. Gene-centric analysis of
 preeclampsia identifies maternal association at PLEKHG1. *Hypertension*.
 2018;72:408–416.
- McGinnis R, Steinthorsdottir V, Williams NO, Thorleifsson G, Shooter S,
 Hjartardottir S, Bumpstead S, Stefansdottir L, Hildyard L, Sigurdsson JK, et al.
 Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. *Nat. Genet.* 2017;49:1255–1260.
- Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A,
 Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep
 phenotyping and genomic data. *Nature*. 2018;562:203–209.
- Mills MC, Rahal C. A scientometric review of genome-wide association studies.
 Commun. Biol. 2019;2:1–11.
- Peterson RE, Kuchenbaecker K, Walters RK, Chen C-Y, Popejoy AB, Periyasamy
 S, Lam M, Iyegbe C, Strawbridge RJ, Brick L, et al. Genome-wide association
 studies in ancestrally diverse populations: opportunities, methods, pitfalls, and
 recommendations. *Cell*. 2019;179:589–603.
- 422 28. Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HMT, Guerrero RF,
 423 Schuermans A, Selvaraj MS, Patel AP, et al. Polygenic prediction of preeclampsia
 424 and gestational hypertension. *Nat. Med.* 2023;29:1540–1549.
- Pan UKBB | Pan UKBB [Internet]. [cited 2021 Mar 30];Available from:
 https://pan.ukbb.broadinstitute.org/
- 30. National Institute of Environmental Health Sciences (NIEHS). Personalized
 Environment and Genes Study [Internet]. clinicaltrials.gov; 2022 [cited 2022 Sep
 Available from: https://clinicaltrials.gov/ct2/show/NCT00341237
- Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
 relationship inference in genome-wide association studies. *Bioinformatics*.
 2010;26:2867–2873.
- Maples BK, Gravel S, Kenny EE, Bustamante CD. RFMix: a discriminative
 modeling approach for rapid and robust local-ancestry inference. *Am. J. Hum. Genet.* 2013;93:278–288.
- Biaz-Papkovich A, Anderson-Trocmé L, Ben-Eghan C, Gravel S. UMAP reveals
 cryptic population structure and phenotype heterogeneity in large genomic
 cohorts. *PLOS Genet.* 2019;15:e1008432.

| 639 640 | 34. : | Return 2442 [Internet]. [cited 2023 Jul 19];Available from: https://biobank.ndph.ox.ac.uk/ukb/dset.cgi?id=2442 |
|--|-------|--|
| 641 642 643 644 | 35. | Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second- generation PLINK: rising to the challenge of larger and richer datasets. <i>GigaScience</i> [Internet]. 2015 [cited 2021 Aug 30];4. Available from: https://doi.org/10.1186/s13742-015-0047-8 |
| 645 646 | 36. | FIRTH D. Bias reduction of maximum likelihood estimates. <i>Biometrika</i> . 1993;80:27–38. |
| 647 648 649 650 651 652 | 37. | Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Madden PAF, Heath AC, Martin NG, Montgomery GW, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. <i>Nat.</i> <i>Genet.</i> 2012;44:369–375, S1-3. |
| 653 654 | 38. | Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. <i>Bioinformatics</i> . 2010;26:2190–2191. |
| 655 656 657 | 39. | Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, Fernandez Banet J, Billis K, García Girón C, Hourlier T, et al. The Ensembl gene annotation system. <i>Database J. Biol. Databases Curation.</i> 2016;2016:baw093. |
| 658 659 | 40. | de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. <i>PLoS Comput. Biol.</i> 2015;11:e1004219. |
| 660 661 662 | 41. | Zhang S. A simplified protocol for performing MAGMA/H-MAGMA gene set analysis utilizing high-performance computing environments. <i>STAR Protoc.</i> 2022;3:101083. |
| 663 664 | 42. | Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28:27–30. |
| 665 666 667 | 43. | Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. <i>Nucleic Acids Res.</i> 2021;49:D545–D551. |
| 668 669 | 44. | Kauko A, Aittokallio J, Vaura F, Ji H, Ebinger JE, Niiranen T, Cheng S. Sex differences in genetic risk for hypertension. <i>Hypertension</i> . 2021;78:1153–1155. |
| 670 671 672 673 | 45. | Huebner H, Hartner A, Rascher W, Strick RR, Kehl S, Heindl F, Wachter DL, Beckmann MW, Fahlbusch FB, Ruebner M. Expression and regulation of retinoic acid receptor responders in the human placenta. <i>Reprod. Sci.</i> 2018;25:1357–1370. |
| | | |

- 46. RARB retinoic acid receptor beta [Homo sapiens (human)] Gene NCBI
- [Internet]. [cited 2022 Sep 24];Available from:
- 676 https://www.ncbi.nlm.nih.gov/gene/5915#summary
- 47. Rhinn M, Dollé P. Retinoic acid signalling during development. *Development*.
 2012;139:843–858.
- 48. Rajakumar A, Kane MA, Yu J, Taylor RN, Sidell N. Aberrant retinoic acid
 production in the decidua: Implications for pre-eclampsia. *J. Obstet. Gynaecol. Res.* 2020;46:1007–1016.
- 49. Nieves-Colón MA, Badillo Rivera KM, Sandoval K, Villanueva Dávalos V,
 Enriquez Lencinas LE, Mendoza-Revilla J, Adhikari K, González-Buenfil R, Chen
 JW, Zhang ET, et al. Clotting factor genes are associated with preeclampsia in
 high-altitude pregnant women in the Peruvian Andes. *Am. J. Hum. Genet.*2022;109:1117–1139.
- 50. Liu X, White S, Peng B, Johnson AD, Brody JA, Li AH, Huang Z, Carroll A, Wei P,
 Gibbs R, et al. WGSA: an annotation pipeline for human genome sequencing
 studies. *J. Med. Genet.* 2016;53:111–112.
- Løset M, Johnson MP, Melton PE, Ang W, Huang R-C, Mori TA, Beilin LJ, Pennell
 C, Roten LT, Iversen A-C, et al. Preeclampsia and cardiovascular disease share
 genetic risk factors on chromosome 2q22. *Pregnancy Hypertens. Int. J. Womens Cardiovasc. Health.* 2014;4:178–185.
- 69452.LaMarca B. Endothelial dysfunction; an important mediator in the Pathophysiology695of Hypertension during Preeclampsia. *Minerva Ginecol.* 2012;64:309–320.
- 53. Trivett C, Lees ZJ, Freeman DJ. Adipose tissue function in healthy pregnancy,
 gestational diabetes mellitus and pre-eclampsia. *Eur. J. Clin. Nutr.* 2021;75:1745–
 1756.
- 54. Staff AC. The two-stage placental model of preeclampsia: An update. *J. Reprod. Immunol.* 2019;134–135:1–10.
- 55. Li X, Tan H, Huang X, Zhou S, Hu S, Wang X, Xu X, Liu Q, Wen SW. Similarities
 and differences between the risk factors for gestational hypertension and
 preeclampsia: A population based cohort study in south China. *Pregnancy Hypertens.* 2016;6:66–71.
- Tyrmi JS, Kaartokallio T, Lokki AI, Jääskeläinen T, Kortelainen E, Ruotsalainen S,
 Karjalainen J, Ripatti S, Kivioja A, Laisk T, et al. Genetic risk factors associated
 with preeclampsia and hypertensive disorders of pregnancy. *JAMA Cardiol.*2023;8:674–683.
- 57. Nurkkala J, Kauko A, FinnGen, Laivuori H, Saarela T, Tyrmi JS, Vaura F, Cheng
 S, Bello NA, Aittokallio J, et al. Associations of polygenic risk scores for

- preeclampsia and blood pressure with hypertensive disorders of pregnancy. *J. Hypertens.* 2023;41:380.
- 58. gatk4-genome-processing-pipeline [Internet]. 2022 [cited 2022 Sep 6];Available
 from: https://github.com/gatk-workflows/gatk4-genome-processing-pipeline
- 59. Auwera GAV der, O'Connor BD. Genomics in the cloud: Using Docker, GATK, and
 WDL in Terra. O'Reilly Media, Inc.; 2020.
- 60. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA MEM [Internet]. 2013 [cited 2022 Sep 6];Available from:
 http://arxiv.org/abs/1303.3997
- Picard Tools By Broad Institute [Internet]. [cited 2022 Sep 6]; Available from:
 https://broadinstitute.github.io/picard/
- 62. applybqsr Clara Parabricks v3.7 documentation [Internet]. [cited 2022 Sep
 6];Available from:
- https://docs.nvidia.com/clara/parabricks/3.7.0/Documentation/ToolDocs/man_appl
 ybqsr.html
- 63. DeepVariant [Internet]. 2022 [cited 2022 Sep 6];Available from:
 https://github.com/google/deepvariant
- 64. Liu X, White S, Peng B, Johnson AD, Brody JA, Li AH, Huang Z, Carroll A, Wei P,
 Gibbs R, et al. WGSA: an annotation pipeline for human genome sequencing
 studies. *J. Med. Genet.* 2016;53:111–112.
- 65. Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, Fernandez Banet J,
 Billis K, García Girón C, Hourlier T, et al. The Ensembl gene annotation system.
 Database J. Biol. Databases Curation. 2016;2016:baw093.
- 66. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
 relationship inference in genome-wide association studies. *Bioinformatics*.
 2010;26:2867–2873.
- 737 67. Population Structure and Relatedness Inference using the GENESIS Package
 738 [Internet]. [cited 2021 Feb 28];Available from:
- https://www.bioconductor.org/packages/devel/bioc/vignettes/GENESIS/inst/doc/pc
 air.html
- 68. Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for
 ancestry prediction and correction of stratification in the presence of relatedness.
 Genet. Epidemiol. 2015;39:276–293.
- 69. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance
 computing toolset for relatedness and principal component analysis of SNP data.
 Bioinformatics. 2012;28:3326–3328.

| 747 748 | 70. Delaneau O, Zagury J-F, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and integrative haplotype estimation. <i>Nat. Commun.</i> 2019;10:5436. |
|-------------------|---|
| 749 | Maples BK, Gravel S, Kenny EE, Bustamante CD. RFMix: a discriminative modeling |
| 750 | approach for rapid and robust local-ancestry inference. <i>Am. J. Hum. Genet.</i> |
| 751 | 2013;93:278–288. |
| 752 | 72. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, Corvelo A, |
| 753 | Clarke WE, Musunuri R, Nagulapalli K, et al. High-coverage whole-genome |
| 754 | sequencing of the expanded 1000 Genomes Project cohort including 602 trios. |
| 755 | <i>Cell.</i> 2022;185:3426-3440.e19. |
| 756 | 73. IGSR samples [Internet]. [cited 2022 May 9];Available from: |
| 757 | https://www.internationalgenome.org/data-portal/sample |
| 758 759 760 | 74. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic data. <i>Nature</i> . 2018;562:203–209. |
| 761 | 75. Category 100319 [Internet]. [cited 2022 Sep 9];Available from: |
| 762 | https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=100319 |
| 763 | 76. Resource 1671 [Internet]. [cited 2022 Sep 9];Available from: |
| 764 | https://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=1671 |
| 765 | 77.: Return 2442 [Internet]. [cited 2023 Jul 19];Available from: |
| 766 | https://biobank.ndph.ox.ac.uk/ukb/dset.cgi?id=2442 |
| 767 | 78. Quality Control (QC) Pan UKBB [Internet]. [cited 2021 Apr 9];Available from: |
| 768 | https://pan-dev.ukbb.broadinstitute.org/docs/qc |
| 769 | 79. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation |
| 770 | PLINK: rising to the challenge of larger and richer datasets. <i>GigaScience</i> |
| 771 | [Internet]. 2015 [cited 2021 Aug 30];4. Available from: |
| 772 | https://doi.org/10.1186/s13742-015-0047-8 |
| 773 | 80. Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric |
| 774 | Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis |
| 775 | (DIAGRAM) Consortium, Madden PAF, Heath AC, Martin NG, Montgomery GW, |
| 776 | et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics |
| 777 | identifies additional variants influencing complex traits. <i>Nat. Genet.</i> 2012;44:369– |
| 778 | 375, S1-3. |
| 779 780 | 81. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. <i>Bioinformatics</i> . 2010;26:2190–2191. |

| 781 782 783 | BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. <i>Bioinforma. Oxf. Engl.</i> 2005;21:3439–3440. |
|-------------------|--|
| 784 785 786 | Barrinek S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. <i>Nat. Protoc.</i> 2009;4:1184–1191. |
| 787 788 | 84. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. <i>PLoS Comput. Biol.</i> 2015;11:e1004219. |
| 789 790 791 | Zhang S. A simplified protocol for performing MAGMA/H-MAGMA gene set analysis utilizing high-performance computing environments. STAR Protoc. 2022;3:101083. |
| 792 793 794 | Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. <i>Cell Syst.</i> 2015;1:417–425. |
| 795 796 | 87. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. <i>Nucleic Acids Res.</i> 2000;28:27–30. |
| 797 798 799 | Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. <i>Nucleic Acids Res.</i> 2021;49:D545– D551. |
| 800 801 | 89. Kauko A, Aittokallio J, Vaura F, Ji H, Ebinger JE, Niiranen T, Cheng S. Sex differences in genetic risk for hypertension. <i>Hypertension</i> . 2021;78:1153–1155. |
| 802 803 804 | Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HMT, Guerrero RF, Schuermans A, Selvaraj MS, Patel AP, et al. Polygenic prediction of preeclampsia and gestational hypertension. <i>Nat. Med.</i> 2023;29:1540–1549. |
| 805 | |
| 806 | |
| 807 | |
| 808 | |
| 809 | |
| 811 | |
| 812 | |
| 813 | |
| | |

814

815 Tables

| (which was not certified by peer revie | w) is the author/funder. who has | s aranted medRxiv a license to | display the preprint in perpe | tuity. |
|---|---|---|--------------------------------------|----------------|
| This article is a US Govern | ment work. It is not subject to co Study for sampler a C | pyright under 17 USC 105 and CC0 licente P Cases | l is also made available Controls | $_{22}P$ value |
| | n = 1,771 | n = 202 | n = 1,569 | 33 |
| Hypertensive Disorders of Pregnancy, n (%) | | | | |
| Gestational hypertension | 202 (11.4) | 202 (100.0) | 0 (0.0) | <0.001* |
| Number of pregnancies with gestational hypertension | | | | |
| 1 | 97 (5.5) | 97 (48.0) | 0 (0.0) | |
| 2 | 24 (1.4) | 24 (11.9) | 0 (0.0) | 0.004 |
| 3 or more | 14 (0.9) | 14 (6.9) | 0 (0.0) | <0.001* |
| Missing | 1636 (92.4) | 67 (33.2) | 1569 (100.0) | |
| Gestational hypertension without preeclampsia | 78 (4.4) | 78 (38.6) | 0 (0.0) | <0.001* |
| Preeclampsia | 71 (4.0) | 71 (35.2) | 0 (0.0) | |
| Number of pregnancies with preeclampsia complication | | | | |
| 1 | 58 (3.3) | 58 (28.7) | 0 (0.0) | |
| 2 | 4 (0.2) | 4 (2.0) | 0 (0.0) | -0.001* |
| 3 or more | 5 (0.3) | 5 (2.5) | 0 (0.0) | <0.001 |
| Missing | 1704 (96.2) | 135 (66.8) | 1569 (100.0) | |
| Gestational hypertension and/or preeclampsia | 202 (11.4) | 202 (100.0) | 0 (0.0) | <0.001* |
| Covariates | | | | |
| Age at enrollment, mean (SD) BML at enrollment, median | 47.2 (13.6) | 44.8 (12.7) | 47.5 (13.7) | 0.0071† |
| (IQR) | 27.4 (23.4, 32.6) | 28.7 (25.0, 34.9) | 27.3 (23.2, 32.3) | <0.001‡ |
| Gravidity, median (IQR) Race/ethnicity, n(%) | 3.0 (2.0, 4.0) | 4.0 (3.0, 5.0) | 3.0 (2.0, 4.0) | <0.001‡ |
| American Indian/Alaskan Native | 16 (0.9) | 1 (0.5) | 15 (1.0) | |
| Asian | 39 (2.2) | 3 (1.5) | 36 (2.3) | |
| Black | 358 (20.2) | 45 (22.3) | 313 (20.0) | |
| Hispanic/Latino | 47 (2.7) | 3 (1.5) | 44 (2.8) | 0.1878* |
| White | 1256 (70.9) | 138 (68.3) | 1118 (71.3) | 0.1070 |
| Other (Multiple or Native Hawaiian/Pacific Islander) | 22 (1.2) | 5 (2.5) | 17 (1.1) | |
| Unknown | 33 (1.9) | 7 (3.5) | 26 (1.7) | |
| | | | | |

34

| Predominant genetic similarity group African Admixed American East Asian European South Asian No group | 382 (21.6) 8 (0.5) 25 (1.4) 1328 (75.0) 15 (0.8) 13 (0.7) | 49 (24.3) 0 (0.0) 1 (0.5) 150 (74.3) 2 (1.0) 0 (0.0) | 333 (21.2) 8 (0.5) 24 (1.5) 1178 (75.1) 13 (0.8) 13 (0.8) | 0.4288* |
|--|--|---|--|---------|
| Socioeconomic Characteristics, n (%) Educational Level at Enrollment High school education or less Some college or technical/vocational school Bachelor's degree Graduate or professional degree Missing | 183 (10.3) 549 (31.0) 530 (29.9) 495 (28.0) 14 (0.8) | 14 (6.9) 73 (36.1) 57 (28.2) 57 (28.2) 1 (0.5) | 169 (10.8) 476 (30.3) 473 (30.2) 438 (27.9) 13 (0.8) | 0.2900* |
| Income at Enrolment (USD) Less than \$50,000 \$50,000 - \$79,999 \$80,000 or more Missing | 659 (37.2) 441 (24.9) 603 (34.0) 68 (3.8) | 69 (34.2) 62 (30.7) 66 (32.7) 5 (2.5) | 590 (37.6) 379 (24.2) 537 (34.2) 63 (4.0) | 0.1810* |

Table 1. Demographic characteristics of participants in the PEGS discovery cohort.

* The *P* values were computed by Fisher's exact test.

† The P value was computed by t-test.

⁺ The *P* values were computed by performing the Mann-Whitney U test.

| 810 | | | |
|-----|--|--|--|
| 817 | | | |
| 818 | | | |
| 819 | | | |
| 820 | | | |
| 821 | | | |
| 822 | | | |
| 823 | | | |

| | | | | Multi-ancestry GWAS | | | Joint analysis | | |
|---------|--------------|--------------|----------------|---------------------|----------------------------|------------------------------|-------------------------|----------|--|
| | | | | | (202 cases/1,569 controls) | | | in GWAS | |
| Nearest | | | Effect Allele/ | | | | | | |
| Gene | Lead Variant | Chr:Position | Other Allele | EAF | OR | 95% CI | Р | Р | |
| LRP1B | rs114954125 | 2:139978665 | G/A | 0.051 | 3.03 | 2.05-4.49 | 3.19E-08 | 3.79E-08 | |
| RARB | rs61176331 | 3:24930847 | A/C | 0.048 | 3.09 | 2.11-4.53 | 7.97E-09 | 9.56E-09 | |
| | | | | | Ger | netic Similari African De | ty Group for escent | | |
| | | | | | (| (49 cases/333 | s controls) | | |
| Nearest | | | Effect Allele/ | | | | | | |
| Gene | Lead Variant | Chr:Position | Other Allele | EAF | OR | 95% CI | Р | | |
| RARB | rs61176331 | 3:24930847 | A/C | 0.042 | 6.98 | 2.97-16.42 | 8.32E-06 | | |
| | | | | | Ger | netic Similari European D | ty Group for Descent | | |
| | | | | | (1 | 50 cases/1,17 | 78 controls) | | |
| Nearest | | | Effect Allele/ | | | | | | |
| Gene | Lead Variant | Chr:Position | Other Allele | EAF | OR | 95% CI | Р | | |
| LRP1B | rs114954125 | 2:139978665 | G/A | 0.067 | 2.95 | 1.97-4.42 | 1.47E-07 | | |
| RARB | rs61176331 | 3:24930847 | A/C | 0.051 | 2.37 | 1.51-3.74 | 1.92E-04 | | |
| | | | | | | Validat | ion | | |

(1,319 cases/2,050 controls)

| Nearest | | | Effect Allele/ | | | | |
|---------|--------------|--------------|----------------|-------|------|---------------|--------------|
| Gene | Lead Variant | Chr:Position | Other Allele | EAF | OR | 95% CI | Р |
| LRP1B | rs114954125 | 2:139978665 | G/A | 0.061 | 1.02 | 0.83-1.27 | 8.34E-01 |
| RARB | rs61176331 | 3:24930847 | A/C | 0.045 | 1.29 | 1.02-1.65 | 3.73E-02 |
| | | | | | | GWAS + Va | lidation |
| | | | | | (1, | 521 cases/3,6 | 19 controls) |
| Nearest | | | Effect Allele/ | | | | |
| Gene | Lead Variant | Chr:Position | Other Allele | EAF | OR | 95% CI | Р |
| LRP1B | rs114954125 | 2:139978665 | G/A | 0.059 | 1.31 | 1.09-1.58 | 4.64E-03 |
| RARB | rs61176331 | 3:24930847 | A/C | 0.046 | 1.66 | 1.35-2.04 | 1.27E-06 |
| | | | | | | | |

Table 2. Summary statistics for rs114954125 (*LRP1B*) and rs61176331 (*RARB*). Chr = chromosome, EAF = effect allele frequency









Figure 2. Manhattan plot of gene-based association analysis of hypertensive disorders of pregnancy. Labeled genes represent the nearest gene within 50 kb upstream or downstream of the gene.



- Figure 3. Gene-set analysis using KEGG with MAGMA. The ten most significant KEGG sets are shown on the y-axis. Corresponding
 unadjusted -log₁₀(p-values) are shown on the x-axis. *P* values were estimated by linear regression model-based testing using
 MAGMA.

-

| | | | Overall | | |
|-----------------------------|--------------------------|-------------------|-------------|------------------|---------------------------------------|
| | 202 cases/1.569 controls | | | | |
| Polygenic Score | OR | (95% CI) | P-value | AUC (95% CI) | - |
| | per SD | . , | | | |
| Systolic blood pressure [1] | 2.09 | 1.40-3.13 | 3.06E-04 | 0.57 (0.52-0.61) | |
| Preeclampsia/eclampsia | 2.88 | 1.05-7.93 | 3.95E-02 | 0.53 (0.49-0.58) | Systolic blood pressure [1] |
| Gestational hypertension | 150.3 | 5.60-4116.9 | 2.79E-03 | 0.56 (0.52-0.60) | |
| Systolic blood pressure [2] | 1.77 | 1.10-2.85 | 1.83E-02 | 0.56 (0.52-0.60) | · · · · · · · · · · · · · · · · · · · |
| | Gen | etic Similarity (| Group for A | frican Descent | Preeclampsia/eclampsia |
| | | 49 case | s/333 contr | ols | |
| Polygenic Score | OR | (95% CI) | P-value | AUC (95% CI) | |
| | per SD | | | | Gestational Hypertension |
| Systolic blood pressure [1] | 1.90 | 0.70-5.23 | 2.09E-01 | 0.52 (0.44-0.61) | → () |
| Preeclampsia/eclampsia | 0.43 | 0.05-3.71 | 4.44E-01 | 0.52 (0.43-0.62) | |
| Gestational hypertension | 50.8 | 0.07-40717.6 | 2.42E-01 | 0.56 (0.47-0.65) | Systolic blood pressure [2] |
| Systolic blood pressure [2] | 1.13 | 0.47-2.79 | 7.81E-01 | 0.56 (0.47-0.64) | |
| | Gene | tic Similarity G | roup for Eu | ropean Descent | |
| | | 150 cases | s/1,178 con | trols | 012345078 |
| Polygenic Score | OR | (95% CI) | P-value | AUC (95% CI) | Overall Odds Patio por SD |
| | per SD | | | | African |
| Systolic blood pressure [1] | 2.31 | 1.47-3.65 | 2.44E-04 | 0.60 (0.55-0.65) | European |
| Preeclampsia/eclampsia | 4.55 | 1.43-14.68 | 1.05E-02 | 0.56 (0.51-0.61) | |
| Gestational hypertension | 337.6 | 7.24-16325 | 2.94E-03 | 0.57 (0.53-0.62) | |
| Systolic blood pressure [2] | 2.08 | 1.19-3.65 | 1.06E-02 | 0.58 (0.53-0.62) | |

- **Figure 4.** Polygenic score summary statistics and forest plot for odds ratio (ORs) per standard deviation (SD) for hypertensive
- disorders of pregnancy in multi-ancestry models and African and European genetic similarity groups. AUC: area under the curve